Aura Biosciences, Inc. Financials
This page shows Aura Biosciences, Inc. (AURA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Aura’s economics are defined by equity-funded R&D spending: losses consume cash directly while the balance sheet stays lightly leveraged.
From FY2024 to FY2025, operating cash burn worsened from$79.8M to$84.7M as the research program expanded. Yet cash rose from$31.7M to$59.5M because financing supplied new capital, meaning the stronger year-end cash position came from shareholders rather than from a cheaper operating model.
Earnings quality is straightforward: FY2025 net loss of
The spending mix is becoming more research-heavy: R&D reached
Financial Health Signals
Aura Biosciences, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Aura Biosciences, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Aura Biosciences, Inc. reported a net loss of $106.2M while operations used $84.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Aura Biosciences, Inc.'s EBITDA was -$111.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 17.7% from the prior year.
Aura Biosciences, Inc. reported -$106.2M in net income in fiscal year 2025. This represents a decrease of 22.2% from the prior year.
Aura Biosciences, Inc. earned -$1.76 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 0.6% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Aura Biosciences, Inc. recorded an outflow of $85.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 5.1% from the prior year.
Aura Biosciences, Inc. held $59.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Aura Biosciences, Inc.'s ROE was -77.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 20.4 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Aura Biosciences, Inc. invested $90.3M in research and development in fiscal year 2025. This represents an increase of 23.2% from the prior year.
Aura Biosciences, Inc. invested $447K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 64.3% from the prior year.
Not reported for fiscal year 2025.
AURA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $90.3M+23.2% | $73.3M+12.4% | $65.2M+54.4% | $42.2M+67.9% | $25.2M+39.5% | $18.0M |
| SG&A Expenses | N/A | $22.5M-1.4% | $22.8M+15.5% | $19.8M+9.4% | $18.1M+79.0% | $10.1M+142.3% | $4.2M |
| Operating Income | N/A | -$112.8M-17.3% | -$96.1M-13.1% | -$85.0M-41.0% | -$60.3M-71.0% | -$35.3M-58.7% | -$22.2M |
| Income Tax | N/A | $108K-3.6% | $112K-18.2% | $137K | $0 | $0 | $0 |
| Net Income | N/A | -$106.2M-22.2% | -$86.9M-13.8% | -$76.4M-30.0% | -$58.8M-66.7% | -$35.3M-58.7% | -$22.2M |
| EPS (Diluted) | — | -$1.76-0.6% | -$1.75+9.3% | -$1.93+1.5% | -$1.96 | -$8.95 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AURA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $169.4M-7.2% | $182.5M-28.5% | $255.1M+13.9% | $223.9M+39.9% | $160.0M+624.0% | $22.1M |
| Current Assets | $149.7M-6.8% | $160.6M-30.7% | $231.8M+17.8% | $196.7M+28.0% | $153.7M+732.9% | $18.5M |
| Cash & Equivalents | $59.5M+87.8% | $31.7M-22.8% | $41.1M-66.2% | $121.6M-18.4% | $149.1M+757.0% | $17.4M |
| Total Liabilities | $32.5M+6.5% | $30.5M+4.5% | $29.2M+3.1% | $28.4M+267.5% | $7.7M-94.1% | $130.8M |
| Current Liabilities | $18.4M+23.3% | $14.9M+20.7% | $12.4M+18.2% | $10.5M+42.2% | $7.4M+176.4% | $2.7M |
| Total Equity | $136.9M-9.9% | $152.0M-32.7% | $225.8M+15.5% | $195.6M+28.4% | $152.3M+240.1% | -$108.7M |
| Retained Earnings | -$480.4M-28.4% | -$374.2M-30.3% | -$287.3M-36.2% | -$210.9M-38.6% | -$152.1M-30.2% | -$116.9M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
AURA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$103.0M | -$84.7M-6.2% | -$79.8M-25.0% | -$63.8M-16.9% | -$54.6M-68.5% | -$32.4M-33.3% | -$24.3M |
| Capital Expenditures | $344K | $447K-64.3% | $1.3M+76.7% | $709K-35.2% | $1.1M-48.5% | $2.1M+175.6% | $771K |
| Free Cash Flow | -$103.4M | -$85.2M-5.1% | -$81.1M-25.6% | -$64.6M-15.9% | -$55.7M-61.3% | -$34.5M-37.6% | -$25.1M |
| Investing Cash Flow | -$185.3M | $35.6M-48.3% | $68.8M+160.4% | -$114.0M-67.9% | -$67.9M-3093.8% | -$2.1M-175.6% | -$771K |
| Financing Cash Flow | $249.2M | $77.2M+4737.3% | $1.6M-98.4% | $97.3M+1.7% | $95.6M-42.5% | $166.3M+1556.6% | $10.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AURA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Return on Equity | -77.6%-20.4pp | -57.2%-23.4pp | -33.8%-3.8pp | -30.0%-6.9pp | -23.1% | N/A |
| Return on Assets | -62.7%-15.1pp | -47.6%-17.7pp | -30.0%-3.7pp | -26.2%-4.2pp | -22.0%+78.4pp | -100.5% |
| Current Ratio | 8.15-2.6x | 10.77-8.0x | 18.76-0.1x | 18.81-2.1x | 20.90+14.0x | 6.94 |
| Debt-to-Equity | 0.240.0x | 0.20+0.1x | 0.130.0x | 0.14+0.1x | 0.05 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Aura Biosciences, Inc. Ranks
Frequently Asked Questions
Is Aura Biosciences, Inc. profitable?
No, Aura Biosciences, Inc. (AURA) reported a net income of -$106.2M in fiscal year 2025.
What is Aura Biosciences, Inc.'s EBITDA?
Aura Biosciences, Inc. (AURA) had EBITDA of -$111.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aura Biosciences, Inc.'s return on equity (ROE)?
Aura Biosciences, Inc. (AURA) has a return on equity of -77.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aura Biosciences, Inc.'s free cash flow?
Aura Biosciences, Inc. (AURA) recorded an outflow of $85.2M in free cash flow during fiscal year 2025. This represents a -5.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aura Biosciences, Inc.'s operating cash flow?
Aura Biosciences, Inc. (AURA) recorded an outflow of $84.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Aura Biosciences, Inc.'s total assets?
Aura Biosciences, Inc. (AURA) had $169.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Aura Biosciences, Inc.'s capital expenditures?
Aura Biosciences, Inc. (AURA) invested $447K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Aura Biosciences, Inc. spend on research and development?
Aura Biosciences, Inc. (AURA) invested $90.3M in research and development during fiscal year 2025.
What is Aura Biosciences, Inc.'s current ratio?
Aura Biosciences, Inc. (AURA) had a current ratio of 8.15 as of fiscal year 2025, which is generally considered healthy.
What is Aura Biosciences, Inc.'s debt-to-equity ratio?
Aura Biosciences, Inc. (AURA) had a debt-to-equity ratio of 0.24 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aura Biosciences, Inc.'s return on assets (ROA)?
Aura Biosciences, Inc. (AURA) had a return on assets of -62.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Aura Biosciences, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Aura Biosciences, Inc. (AURA) held $59.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $84.7M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Aura Biosciences, Inc.'s Piotroski F-Score?
Aura Biosciences, Inc. (AURA) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aura Biosciences, Inc.'s earnings high quality?
Aura Biosciences, Inc. (AURA) reported a net loss of $106.2M while operations used $84.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.